检索范围:
排序: 展示方式:
Meng Lv, Yingjun Chang, Xiaojun Huang
《医学前沿(英文)》 2019年 第13卷 第1期 页码 45-56 doi: 10.1007/s11684-017-0595-7
关键词: haploidentical hematopoietic stem cell transplantation conditioning graft-versus-host disease relapse infection donor selection
Lijuan Hu, Qi Wang, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Kaiyan Liu, Hui Wang, Xiaojun Huang, Xiaodong Mo
《医学前沿(英文)》 2019年 第13卷 第4期 页码 492-503 doi: 10.1007/s11684-019-0681-0
关键词: haploidentical hematopoietic stem cell transplantation stool culture Candida
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 224-228 doi: 10.1007/s11684-017-0538-3
Bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HSCT) is a major cause of morbidity and mortality with limited treatment options. Lung transplantation (LTX) has been rarely reported as a treatment option for selected HSCT recipients with this problem. In the present study, we reported six patients who underwent LTX due to BOS after HSCT (two females, four males) from January 2012 to December 2014 in our center. The median time from HSCT to diagnosis of BOS was 2.5 years (ranging from 1 to 5 years). At a median time of 4 years (ranging from 2 to 5 years) after diagnosis of BOS, four patients received bilateral sequential LTX, and two patients received single LTX. One of the recipients suffered from mild acute rejection after LTX, another suffered from primary lung graft dysfunction on post-operation day 2, and three experienced fungal infections. The median time for follow-up after LTX was 19.5 months (ranging from 12 to 39 months). At present, all patients are alive with good functional capacity and no relapse of BOS and hematologic malignancy conditions. Patients who received bilateral LTX have better pulmonary functions than patients who received single LTX.
关键词: bronchiolitis obliterans syndrome (BOS) hematopoietic stem cell transplantation (HSCT) lung transplantation (LTX)
《医学前沿(英文)》 2022年 第16卷 第6期 页码 957-968 doi: 10.1007/s11684-021-0910-1
关键词: skin and soft tissue infections hematopoietic stem cell transplantation risk stratification system mortality
null
《医学前沿(英文)》 2015年 第9卷 第3期 页码 304-311 doi: 10.1007/s11684-015-0400-4
In the tyrosine kinase inhibitor (TKI) era, imatinib is the first-line therapy for patients with chronic myeloid leukemia (CML) in chronic or accelerated phase. Although second-generation TKIs (TKI2), including dasatinib and nilotinib, are appropriate treatment regimens for patients with disease that progressed to accelerated phase following imatinib therapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy. This study retrospectively analyzed the efficacy of TKI2 and HSCT for treatment of CML in accelerated phase. Ninety-three patients with CML registered in the Chinese CML alliance database from February 2001 to February 2014 were enrolled and divided into the TKI2 (n?=?33) and allo-HSCT (n?=?60) groups. In the TKI2 group, 26 and 7 patients received nilotinib and dasatinib, respectively, as initial TKI2 and 11 patients transferred to the alternative TKI2 after failure to one TKI2. In the allo-HSCT group, 22 (36.7%), 35 (58.3%), and 3 (10%) patients underwent allo-HSCT from an HLA-matched sibling donor, HLA mismatched/haploidentical donor, and unrelated donor, respectively. All patients in the HSCT group were engrafted. Overall, 69.7%, 48.5%, and 45.5% of patients presented hematological, cytogenetic, and major molecular responses, respectively, to at least one of TKI2. All 60 patients (100%) achieved CHR and cytogenetic response in the HSCT group. Patients in the TKI2 group exhibited lower 5-year overall survival rate (42.9% vs. 86.4%, P = 0.002), 5-year event-free survival rate (14.3% vs. 76.1%, P<0.001), and 5-year progression-free survival (28.6% vs. 78.1%, P<0.001) than those in the allo-HSCT group. Multivariate analysis showed that male sex and TKI2therapy were predictors of poor overall survival, whereas hemoglobin<100 g/L and TKI2 therapy were predictors of poor event-free survival and progression-free survival. These results indicated that allo-HSCT may be superior to nilotinib and dasatinib for adult patients with CML in accelerated phase.
关键词: chronic myeloid leukemia imatinib dasatinib nilotinib allogeneic hematopoietic stem cell transplantation
null
《医学前沿(英文)》 2013年 第7卷 第3期 页码 306-315 doi: 10.1007/s11684-013-0279-x
Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most effective options for hematological malignancies, and human leukocyte antigen-partially matched related donors (PMRDs) are a valuable option for HSCT. Several protocols (with or without ex vivo T-cell depletion (TCD)) have been established worldwide. TCD including CD34+positive selection and CD3/CD19 depletion has successfully overcome the human leukocyte antigen disparity. However, TCD is associated with prolonged immune deficiencies, increased risks of infectious complications, and high transplantation-related mortality. PMRD HSCT without ex vivo TCD is well developed, and numerous patients have benefitted from it. Here, we review the literature on PMRD HSCT.
关键词: partially matched related donor hematopoietic stem cell transplantation allogeneic
Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu
《医学前沿(英文)》 2021年 第15卷 第1期 页码 108-115 doi: 10.1007/s11684-019-0730-8
关键词: post-transplantation cyclophosphamide allogeneic hematopoietic stem cell transplantation lymphoid malignancies
Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus
SUN Ledong, SUN Jing, ZENG Kang, MENG Fanyi, DIAO Youtao, XU Dan, HUANG Liang, ZHAO Jie, Liu Qifa
《医学前沿(英文)》 2008年 第2卷 第2期 页码 191-194 doi: 10.1007/s11684-008-0036-8
关键词: serological activity leukapheresis peripheral hematopoietic cyclophosphamide resistance
Meng Lv, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang, Xiaodong Mo
《医学前沿(英文)》 2019年 第13卷 第6期 页码 667-679 doi: 10.1007/s11684-019-0702-z
关键词: acute graft-versus-host disease chronic graft-versus-host disease National Institutes of Health consensus criteria acute myeloid leukemia anti-thymocyte globulin
疾病危险度-共患病指数在单倍型造血干细胞移植中的应用 Article
莫晓冬, 张晓辉, 许兰平, 王昱, 闫晨华, 陈欢, 陈育红, 韩伟, 王峰蓉, 王景枝, 刘开彦, 黄晓军
《工程(英文)》 2021年 第7卷 第2期 页码 162-169 doi: 10.1016/j.eng.2020.12.005
本文的研究目的是基于疾病危险度指数(disease risk index, DRI)和造血干细胞移植共患病指数(hematopoietic cell transplantation-specificcomorbidity index, HCT-CI),提出适合单倍型造血干细胞移植(haploidentical hematopoietic stem cell transplantation, haplo-HSCT
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 153-163 doi: 10.1007/s11684-017-0548-1
To establish optimal reference values for recovered immune cell subsets, we prospectively investigated post-transplant immune reconstitution (IR) in 144 patients who received allogeneic stem cell transplantation (allo-SCT) and without showing any of the following events: poor graft function, grades II?IV acute graft-versus-host disease (GVHD), serious chronic GVHD, serious bacterial infection, invasive fungal infection, or relapse or death in the first year after transplantation. IR was rapid in monocytes, intermediate in lymphocytes, CD3+ T cells, CD8+ T cells, and CD19+ B cells, and very slow in CD4+ T cells in the entire patient cohort. Immune recovery was generally faster under HLA-matched sibling donor transplantation than under haploidentical transplantation. Results suggest that patients with an IR comparable to the reference values display superior survival, and the levels of recovery in immune cells need not reach those in healthy donor in the first year after transplantation. We suggest that data from this recipient cohort should be used as reference values for post-transplant immune cell counts in patients receiving HSCT.
关键词: immune reconstitution hematopoietic stem cell transplantation event-free patients reference range
In vivo imaging of hematopoietic stem cell development in the zebrafish
Panpan Zhang, Feng Liu
《医学前沿(英文)》 2011年 第5卷 第3期 页码 239-247 doi: 10.1007/s11684-011-0123-0
关键词:
hematopoietic stem cell
hematopoiesis
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang
《医学前沿(英文)》 2019年 第13卷 第3期 页码 354-364 doi: 10.1007/s11684-018-0665-5
关键词: donor leukocyte infusion hematopoietic stem cell transplantation interferon-
《医学前沿(英文)》 2021年 第15卷 第5期 页码 728-739 doi: 10.1007/s11684-021-0833-x
关键词: second hematopoietic stem cell transplantation acute leukemia relapse chemotherapy modified donor lymphocyte infusion
null
《医学前沿(英文)》 2015年 第9卷 第4期 页码 412-420 doi: 10.1007/s11684-015-0423-x
Genetic mutations are considered to drive the development of acute myeloid leukemia (AML). With the rapid progress in sequencing technologies, many newly reported genes that are recurrently mutated in AML have been found to govern the initiation and relapse of AML. These findings suggest the need to distinguish the driver mutations, especially the most primitive single mutation, from the subsequent passenger mutations. Recent research on DNA methyltransferase 3A (DNMT3A) mutations provides the first proof-of-principle investigation on the identification of preleukemic stem cells (pre-LSCs) in AML patients. Although DNMT3A mutations alone may only transform hematopoietic stem cells into pre-LSCs without causing the full-blown leukemia, the function of this driver mutation appear to persist from AML initiation up to relapse. Therefore, identifying and targeting preleukemic mutations, such as DNMT3A mutations, in AML is a promising strategy for treatment and reduction of relapse risk.
关键词: preleukemic stem cell acute myeloid leukemia relapse DNMT3A
标题 作者 时间 类型 操作
Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoieticstem cell transplantation
Meng Lv, Yingjun Chang, Xiaojun Huang
期刊论文
Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem celltransplantation
Lijuan Hu, Qi Wang, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Kaiyan Liu, Hui Wang, Xiaojun Huang, Xiaodong Mo
期刊论文
Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation
null
期刊论文
Risk stratification system for skin and soft tissue infections after allogeneic hematopoietic stem celltransplantation: PAH risk score
期刊论文
Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult
null
期刊论文
Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation
null
期刊论文
Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneicperipheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm
Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu
期刊论文
Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus
SUN Ledong, SUN Jing, ZENG Kang, MENG Fanyi, DIAO Youtao, XU Dan, HUANG Liang, ZHAO Jie, Liu Qifa
期刊论文
Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidenticalhematopoietic stem cell transplantation in acute myeloid leukemia
Meng Lv, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang, Xiaodong Mo
期刊论文
Comparison of reference values for immune recovery between event-free patients receiving haploidentical
null
期刊论文
Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoieticstem cell transplantation
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang
期刊论文
Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed
期刊论文